What steroid regimen and tapering schedule are recommended for an adult with an active ulcerative colitis flare?

Steroid Dosing and Tapering for Ulcerative Colitis

For adults with moderate-to-severe ulcerative colitis, start oral prednisolone 40 mg once daily in the morning and taper gradually over 6-8 weeks; for hospitalized patients with acute severe disease, use intravenous methylprednisolone 40-60 mg/day rather than higher doses. 1, 2

Outpatient Steroid Regimen for Moderate-to-Severe UC

Initial Dosing

• Start prednisolone 40 mg once daily as a single morning dose for moderate-to-severe active ulcerative colitis 2, 3
• This dose is more effective than 20 mg/day, and doses above 40-60 mg/day provide no additional clinical benefit while increasing adverse effects 2
• Single daily dosing is as effective as divided doses and causes less adrenal suppression 2

Tapering Protocol

• Taper prednisolone gradually over 6-8 weeks from initiation to complete discontinuation 1, 2, 3
• More rapid tapering is associated with early relapse 1
• The total duration—from start of therapy to discontinuation—should be 6-8 weeks, not 6-8 weeks of full-dose therapy followed by taper 2

Early Response Assessment

• Evaluate clinical response within 2 weeks of starting corticosteroids 2
• If no adequate response by day 14, escalate to biologic agents (anti-TNF, vedolizumab, ustekinumab) or tofacitinib rather than increasing steroid dose 2
• Approximately 30-50% of patients fail to achieve remission with oral prednisolone and require treatment escalation 2

Inpatient Steroid Regimen for Acute Severe UC

Intravenous Dosing

• Use intravenous methylprednisolone 40-60 mg/day (or hydrocortisone 400 mg/day in divided doses) for hospitalized patients with acute severe ulcerative colitis 1
• Higher doses of intravenous corticosteroids provide no additional benefit and increase adverse effects 1
• Meta-regression analysis shows no correlation between corticosteroid dose (40-100 mg range) and risk of colectomy when baseline disease severity is controlled 2

Response Assessment and Rescue Therapy

• Assess clinical response within 3-5 days of initiating intravenous steroids 2
• Continuing steroids beyond 7 days offers no benefit for non-responders 2
• For patients refractory to intravenous corticosteroids, use infliximab or cyclosporine as rescue therapy 1

Alternative Corticosteroid Formulations

Second-Generation Corticosteroids

• Budesonide MMX 9 mg/day for 8 weeks may be considered for patients who wish to avoid systemic corticosteroids, though it is less effective than prednisolone for moderate-to-severe disease 2
• Beclometasone dipropionate 5 mg/day for 4 weeks has been shown to be non-inferior to prednisolone in mild-to-moderate ulcerative colitis 2
• These agents have reduced systemic absorption and fewer adverse effects but are not appropriate for severe disease 4

Critical Safety Considerations

Adverse Effects

• Approximately 50% of patients experience short-term adverse effects including acne, edema, sleep disturbances, mood changes, glucose intolerance, and dyspepsia 2, 3
• Monitor for infections, hyperglycemia, hypokalemia, and psychiatric symptoms during treatment 5
• Consider GI prophylaxis with proton pump inhibitors for patients on ≥20 mg prednisolone, particularly when combined with other immunosuppressive agents 5

Steroid Dependency and Escalation

• Patients requiring ≥2 courses of corticosteroids within one year or who become steroid-dependent must be escalated to steroid-sparing therapy 2, 3
• Steroid-sparing options include thiopurines (azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day), anti-TNF agents, vedolizumab, ustekinumab, or tofacitinib 1, 2
• Corticosteroids must never be used for long-term maintenance therapy due to ineffectiveness and significant adverse effects including infections, osteoporosis, cataracts, and increased mortality 2, 6, 7

Common Pitfalls to Avoid

• Do not increase prednisolone above 60 mg/day—higher doses provide no additional benefit and increase toxicity 2
• Do not continue oral prednisolone beyond 2 weeks without clinical improvement—this delays necessary escalation to advanced therapies 2
• Do not use corticosteroids for maintenance of remission—they are ineffective for long-term control and cause cumulative harm 2, 6
• Do not taper too rapidly—complete the full 6-8 week taper to minimize relapse risk 1, 2